High risk lymphoblastic leukemia in children: Prognostic factors and management

Blood Reviews

Volumn 1, Issue 1, 1987, Pages 25-33

  Pui, C H ^a   Crist, W M ^a  

^a University of Tennessee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL SURFACE MARKER; MERCAPTOPURINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; CHILD; HUMAN; PROGNOSIS; REVIEW;

CHILD; HUMAN; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; PROGNOSIS; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023620715     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0268-960X(87)90016-6     Document Type: Article

References (78)

1. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries
2. Acute lymphoblastic leukemia
3. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York Regimen—a new intensive therapy protocol: a report from the Children's Cancer Study Group
4. Teniposide (VM26) plus cytarabine (ara-C) improves outcome in extremely high-risk acute lymphocytic leukemia
5. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia
6. Initial features and prognosis in 363 children with acute lymphocytic leukemia
7. Assessment of the interrelationship of prognostic factors in childhood acute lymphoblastic leukemia
8. Clinical relevance of lymphoblast biological features in children with acute lymphoblastic leukemia
9. Serum lactic dehydrogenase level has prognostic value in childhood acute lymphoblastic leukemia
10. Pre-B cell leukemia responds poorly to treatment: A Pediatric Oncology Group Study
11. Clinical and biologic features predict a poor prognosis in acute lymphoid leukemias in infants: A Pediatric Oncology Group Study
12. Age at diagnosis in childhood acute lymphoblastic leukemia
13. Variation by race in presenting clinical and biologic features of childhood acute lymphoblastic leukaemia: implications for treatment outcome
14. Clinical and phenotypic features of childhood acute lymphocytic leukemia in whites, blacks, and hispanics: A Pediatric Oncology Group Study
15. Differences in prognosis for boys and girls with acute lymphoblastic leukaemia
16. Haemoglobin and prognosis in childhood acute lymphoblastic leukaemia
17. Survivals of 5 to 15 years in acute leukemia. A study of 21 children
18. Kidneys very large at diagnosis are associated with poor prognosis in children with acute lymphoblastic leukemia
19. Association between HLA-D region antigens and disease-free survival in childhood non-T, non-B acute lymphocytic leukemia
20. Social class as a prognostic variable in acute lymphoblastic leukaemia
21. Immunologic markers in childhood acute lymphocytic leukemia
22. Pediatric Oncology Group utilization of immunologic markers in the designation of acute lymphocytic leukemia subgroups: influence on treatment response
23. Monoclonal antibody characterization of surface antigens in childhood T-cell lymphoid malignancies
24. Modified LSA2-L2 treatment in 53 children with E-rosette positive T-cell leukemia: results and prognostic factors (A Pediatric Oncology Group Study)
25. Acute lymphoblastic leukemia: current status of therapy in children
26. Bone marrow involvement in Burkitt's lymphoma and its relationship to acute B-cell leukemia
27. +) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine
28. Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society
29. Cytogenetic features and serum lactic dehydrogenase level predict a poor treatment outcome for children with pre-B-cell leukemia
30. Immunologically defined sub-classes of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis
31. Quantitative variation of the common acute lymphoblastic leukemia antigen (gp100) on leukemic marrow blasts
32. Prognostic implications of chromosomal findings in acute lymphoblastic leukemia at diagnosis
33. Third International Workshop on Chromosomes in Leukemia
34. Prognostic importance of chromosome number in 136 untreated children with acute lymphoblastic leukemia
35. Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia
36. Chromosomal translocations play a unique role in influencing prognosis in childhood acute lymphoblastic leukemia
37. French-American-British (FAB) Cooperative Group proposed for the classification of acute leukemias
38. Prognostic implications of blast cell morphology in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group
39. The French-American-British (FAB) classification of leukemia. The Pediatric Oncology Group experience with lymphocytic leukemia
40. Acute leukaemia with mixed lymphoid and myeloid phenotype
41. Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance
42. Clinical pathologic aspects of myeloid antigen positivity in pediatric patients with acute lymphoblastic leukemia (ALL)
43. Glucocorticoid receptors in childhood acute lymphocytic leukemia
44. Relationship of pretreatment lymphoblast proliferative activity and prognosis in 97 children with acute lymphoblastic leukemia
45. A score at diagnosis for predicting length of remission in childhood acute lymphoblastic leukaemia
46. Unfavorable prognostic significance of hand mirror cells in childhood acute lymphoblastic leukemia. A report from the Children's Cancer Study Group
47. Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents. A Pediatric Oncology Group Review
48. Improvement in treatment for children with acute lymphoblastic leukaemia
49. Early results of intensified remission induction chemotherapy for childhood acute lymphocytic leukemia
50. Rationale for the use of alternating non-cross-resistant chemotherapy
51. Acute lymphoblastic leukemia: treatment
52. Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia
53. Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemia
54. Cyclophosphamide-asparaginase-vincristine-prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia
55. Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia
56. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?
57. Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia?
58. Medical Research Council Leukaemia trial UKALL VII A report to the Council by the Working Party on Leukaemia in childhood
59. Clinical pharmacodynamics of high-dose methodtrexate in acute lymphocytic leukemia: identification of a relation between concentration and effect
60. The use of intermediate dose methotrexate in increased risk childhood acute lymphoblastic leukemia. A comparison of three versus six courses
61. Randomized study of 3 years versus 5 years of chemotherapy in childhood acute lymphoblastic leukemia
62. Duration of chemotherapy in childhood acute lymphoblastic leukaemia
63. Elective testicular biopsy during chemotherapy for childhood leukaemia is of no clinical value
64. Intermediate dose methotrexate in childhood acute lymphoblastic leukemia resulting in decreased incidence of testicular relapse
65. Bone marrow transplantation for acute lymphocytic leukemia
66. Bone-marrow transplantation for acute lymphoblastic leukaemia
67. Bone marrow ablation followed by allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia during complete remission
68. Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: A Pediatric Oncology Group Study
69. The relationship of blast cell glucocorticoid receptor levels to response to single-agent steroid trial and remission response in children with acute lymphoblastic leukemia
70. American Burkitt's lymphoma: A clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival
71. Cytosine arabinoside/cyclophosphamide pulses improve prognosis in childhood T-cell acute lymphocytic leukemia (ALL)
72. Pretreatment cytokinetic studies in 94 children with acute leukemia. Relationship to other variables at diagnosis and to outcome of standard treatment
73. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody
74. Treatment of B cell lymphoma with monoclonal anti-idiotype antibody
75. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia
76. Therapeutic selectivity of and prediction of response to 2′-deoxycoformycin in acute leukaemia
77. Impact of treatment efficacy on the prognostic value of glucocorticoid receptor levels in childhood acute lymphoblastic leukemia